Investment Date

June 2025

Employees

c.230

Headquarters

Italy

Sector

Healthcare

Status

Current

A leading Italian-headquartered producer of innovative instrument systems and reagents for the global In-Vitro Diagnostics (IVD) market. DIESSE has two main product lines: (i) instruments and reagents for autoimmunity and infectious diseases and (ii) haematological diagnostic tests. DIESSE has a highly sticky “razor / razor-blade” business model whereby it sells instruments with which only DIESSE’s consumable reagents can be used.

Related news

January 27, 2025

Fremman Capital acquires a majority stake in Italian specialty In Vitro Diagnostics (IVD) leader DIESSE Diagnostica Senese in a bilateral transaction with private equity healthcare specialist ARCHIMED